Advanced search
Publication Cover
Hematology Volume 24, 2019 - Issue 1
Submit an article Journal homepage
2,250
Views
2
CrossRef citations to date
0
Altmetric
Articles

Serum platelet factor 4 is a promising predictor in newly diagnosed patients with multiple myeloma treated with thalidomide and VAD regimens

Ju BaiDepartment of Hematology, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaView further author information
,
Jianli WangDepartment of Hematology, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaView further author information
,
Yun YangDepartment of Hematology, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaView further author information
,
Wanggang ZhangDepartment of Hematology, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaView further author information
,
Fangxia WangDepartment of Hematology, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaView further author information
,
Lei ZhangDepartment of Clinical Lab, Second Affiliated Hospital, Xi'an Jiaotong University, Xi’an, People’s Republic of ChinaView further author information
,
Hongli ChenDepartment of Hematology, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaView further author information
,
Xiaman WangDepartment of Hematology, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaView further author information
,
Yuandong FengDepartment of Hematology, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaView further author information
,
Ying ShenDepartment of Hematology, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaView further author information
,
Lingjuan HuangDepartment of Hematology, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaView further author information
&
Aili HeDepartment of Hematology, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 387-391 | Published online: 19 Mar 2019

Related Research Data

Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate.
Source: American Society of Hematology
International uniform response criteria for multiple myeloma
Source: Springer Science and Business Media LLC
p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation
Source: American Society of Hematology
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management
Source: Wiley
Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo
Source: Springer Nature
Serum platelet factor 4 is a promising predictor in newly diagnosed patients with multiple myeloma treated with thalidomide and VAD regimens
Source: Figshare
Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma
Source: Springer Nature
Angiogenesis in multiple myeloma
Source: Wiley
A survey of prognostic value of serum factors in multiple myeloma patients before treatment: macrophage-colony stimulating factor (M-CSF) is a powerful predictor of survival
Source: Springer Nature
4q loss is potentially an important genetic event in MM tumorigenesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13.3, platelet factor 4
Source: American Society of Hematology
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis
Source: American Society of Hematology
Angiogenesis in multiple myeloma
Source: Wiley
Multiple Myeloma: Diagnosis and Treatment
Source: Elsevier BV
Serum platelet factor 4 is a promising predictor in newly diagnosed patients with multiple myeloma treated with thalidomide and VAD regimens
Source: Taylor & Francis
Multiple Myeloma: Diagnosis and Treatment
Source: Elsevier BV
Angiogenesis in multiple myeloma
Source: Wiley
Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myeloma
Source: Ferrata Storti Foundation (Haematologica)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Source: Elsevier BV
Angiogenesis in multiple myeloma
Source: Wiley
Platelet Factor 4: An Inhibitor of Angiogenesis
Source: Georg Thieme Verlag KG
Serum Platelet Factor 4 Is an Independent Predictor of Survival and Venous Thromboembolism in Patients with Pancreatic Adenocarcinoma
Source: American Association for Cancer Research (AACR)

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.